Acrivon Therapeutics (ACRV) Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
ACRV Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Acrivon Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.96 |
| 52 Week High | US$3.56 |
| 52 Week Low | US$1.20 |
| Beta | 1.83 |
| 1 Month Change | 42.03% |
| 3 Month Change | 25.64% |
| 1 Year Change | 48.48% |
| 3 Year Change | -84.21% |
| 5 Year Change | n/a |
| Change since IPO | -88.22% |
Recent News & Updates
We're Keeping An Eye On Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Will Acrivon Therapeutics (NASDAQ:ACRV) Spend Its Cash Wisely?
NasdaqGM:ACRV 1 Year Share Price vs Fair Value Explore Acrivon Therapeutics's Fair Values from the Community and select...Recent updates
Shareholder Returns
| ACRV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 14.0% | 0.02% | 0.6% |
| 1Y | 48.5% | 36.1% | 19.5% |
Return vs Industry: ACRV exceeded the US Biotechs industry which returned 36.1% over the past year.
Return vs Market: ACRV exceeded the US Market which returned 19.5% over the past year.
Price Volatility
| ACRV volatility | |
|---|---|
| ACRV Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ACRV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ACRV's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 75 | Peter Blume-Jensen | acrivon.com |
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer.
Acrivon Therapeutics, Inc. Fundamentals Summary
| ACRV fundamental statistics | |
|---|---|
| Market cap | US$87.74m |
| Earnings (TTM) | -US$77.27m |
| Revenue (TTM) | n/a |
Is ACRV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACRV income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$77.27m |
| Earnings | -US$77.27m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.81 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ACRV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/10 23:45 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Acrivon Therapeutics, Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Li Wang Watsek | Cantor Fitzgerald & Co. |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |
| Emily Bodnar | H.C. Wainwright & Co. |